Right-to-Win.

Right-to-Win is not your ICP.

The honest Chief Marketing Officer (CMO) move is to run both in parallel. The ICP is the bet you’re making for the next 18 months; Right-to-Win is the truth about where you are today. The Brief stores both. When the two converge, the function is operating well. When they diverge, the divergence itself is the conversation — either the strategy is ahead of the proof, or the proof says the strategy is wrong.

The three intersections — where Right-to-Win lives.

The Venn intersection of all three is the segment where you have an unambiguous right to win. Inside that intersection, your win rate is highest because all three forces are working in your favor at the same time. Outside it, the win rate degrades quickly — you might still close deals, but you’ll close them on the customer’s terms, not yours, and you’ll lose them to the next vendor more easily.

How to find it — the two signals method.

The fastest path to a draft Right-to-Win runs two signals in parallel and then validates the intersection with customer conversations. Both signals are pulled from data you already have; the customer work is the qualitative layer that makes the answer defensible.

Signal 1 — the Sales signal

Pull the last 12 months of closed-won deals from the CRM. For each deal, capture: industry, company size, employee count, Annual Recurring Revenue (ARR), sales cycle length, win source (inbound, outbound, partner), the named competitor in the deal, and the “why us” reason. Filter for deals where the sales cycle was shorter than the team average and the win rate against the named competitor was 60%+.

Then ask the sales team three questions:

1. Which leads do you get most excited about — where do you walk into the call already 70% sure you’ll win?
2. Which companies or buyers have no tradeoffs in the conversation — where you don’t have to apologize for any part of the product?
3. Who has the fastest buying cycles — where the deal closes in under 60 days, with under three meetings?

The pattern you’re looking for is the segment where the answers to all three questions cluster on the same buyer type. That cluster is the first half of the Right-to-Win hypothesis.

Signal 2 — the PLG signal

If you ship a Product-Led Growth (PLG) motion (free tier, trial, freemium, or self-serve sign-up), the activation data is the second signal. Pull the last 12 months of sign-ups by firmographic. Look for:

• Who activates fastest after sign-up? Segment by time-to-first-value — the buyer cluster that hits the activation event within 7 days is the cluster where the product solves the problem immediately, with no implementation overhead.
• Who expands naturally without a Customer Success Manager (CSM) nudge? Look at seat expansion and tier upgrades that happened without a customer-success motion. Those are the buyers where the product genuinely outgrows itself inside the account.
• Who has the lowest churn? Segment by 12-month logo retention. The cluster with retention above 90% is the cluster where the product fits the underlying job-to-be-done at maturity.

Where the Sales signal and the PLG signal both point at the same buyer profile, you have a strong Right-to-Win candidate. If they point at different profiles, run both as separate Right-to-Win hypotheses and let the customer conversations break the tie.

Sales-led-only contingency

If you don’t run a PLG motion (enterprise-only, sales-led, no self-serve product), the PLG signal is replaced by the Customer Success signal:

• Net Promoter Score (NPS) by segment — the cluster with NPS above 50 is the cluster where the product is meeting expectations consistently.
• Expansion velocity by segment — the cluster where net dollar retention is above 130% is the cluster where the relationship is compounding.
• Reference willingness by segment — the cluster where customers say yes to reference calls without hesitation is the cluster where the relationship is healthy enough to publicly advocate.

Validate with the five customer questions.

The data signals point at a hypothesis. The customer conversations validate it — and almost always sharpen it. Pick five customers from the candidate Right-to-Win segment. The ones to pick: a recent closed-won, a high-NPS expansion, a long-tenure logo, a recent reference call participant, and an early adopter who’s been around since before the product was good. The five span the lifecycle and surface different parts of the truth.

Run the same five questions on every call:

1. Why did you choose us? Listen for the specific competitor they were comparing against and the moment in the evaluation when the decision tipped.
2. What were you trying to solve? Listen for the words they use to describe the problem — not the words your marketing uses.
3. Why us over the alternatives? This is the differentiator question. The answer is rarely the feature your team is proud of; it’s usually a positioning or trust factor.
4. What changed after using us? The outcome question — specific, in their measurement system, in their timeframe.
5. What business impact did you see? The quantified answer — cost saved, revenue gained, time recovered, risk reduced.

What you’re listening for across five calls: the recurring phrase. The exact words four or five of them use, unprompted, to describe what you do or who you serve. That phrase is almost always closer to your real Right-to-Win than anything in the existing brand deck. Capture it verbatim — it becomes the language for the statement, the pillars, the homepage hero, and every downstream prompt.

Synthesize into the statement.

The Right-to-Win statement is one sentence. The discipline is in the constraint: if it takes two sentences, you don’t have it yet. The shape is consistent:

Three rules. The segment is specific — not “mid-market healthcare” but “US ambulatory care networks with 25–250 clinic locations running Epic.” The pain is in the customer’s language — not “clinical workflow optimization” but “every clinic runs the intake differently and I can’t standardize the patient experience.” The competitor is named — not “legacy electronic health record (EHR) extensions” but “athenaOne, eClinicalWorks, and NextGen.” Vague Right-to-Win statements drift the moment they meet a real prospect; specific ones survive the meeting.

Worked example

A B2B SaaS selling clinical-workflow software to outpatient health systems runs the two-signals method. The Sales signal points at multi-site ambulatory care networks (25–250 clinic locations) on Epic in the Southeast and Texas; the Customer Success signal points at the same cluster. Five customer conversations surface the recurring phrase: “you’re the first system that was built for how outpatient actually runs.” The synthesized statement:

“We win in US ambulatory care networks with 25–250 clinic locations on Epic because we solve the ‘every clinic runs intake differently’ problem in a way Epic-extension competitors like athenaOne, eClinicalWorks, and NextGen structurally cannot — their workflow models were designed for inpatient operations, not for the throughput rhythm of outpatient — and our customers describe us as the first system that was built for how outpatient actually runs.”

That statement does work. The sales team uses it to qualify in or out. The brand pillars derive from it (outpatient-first workflow design, Epic-native integration depth, clinic-network scale operations). The pricing tiers segment around it (single-clinic buyers pay one price; 25–250 location networks pay a premium because the workflow standardization compounds with footprint). The content calendar leads with outpatient operations for multi-site network leaders, not generic healthcare IT content. Every downstream area gets sharper.

The three intersections behind the statement: (1) clinic-network scale — multi-site networks have a coordination problem single clinics don’t; (2) Epic integration depth — not just integrated, integrated in a way that respects Epic’s workflow primitives; (3) outpatient-first design — built for the 14-minute encounter cycle, not the multi-day inpatient stay. Where all three intersect is the segment where the team is structurally hard to displace.

The 90-day implementation guarantee is the second-order proof that the Right-to-Win is real. Buyers care about implementation speed because every week of delay is revenue lost at each clinic on the rollout list. The statement holds because the team can defend it: under 90 days to live across a 50-clinic network is empirically verifiable; the integration with Epic and Athena handles the reconciliation problem the buyer used to staff a small team to manage; and the workflow design assumes outpatient cycle times from the first screen onward.

What the Right-to-Win unlocks downstream.

The Brief field is the dependency that every downstream prompt in the playbook reads. The flow:

Without a Brief-level Right-to-Win, each of these areas makes its own assumption about who you sell to and where you win. They drift apart. With a shared Right-to-Win, they compound on the same buyer.

The biannual refresh cadence.

Right-to-Win is not a one-time exercise. The data changes — competitors reposition, the product expands, the buyer matures, the macro environment shifts. The discipline is a structured refresh every six months, ideally at the start of H1 planning and again at mid-year.

The refresh is three steps: (1) re-pull the Sales and PLG signals against the last 12 months; (2) re-run the five-questions interview with five new customers; (3) ask whether the statement still reads as true. If it does, sign it again and keep it. If it doesn’t, draft a v2 and circulate it through leadership, sales, and CS for stress-testing before adopting.

Brief-builder: your Sales signal evidence

Brief-builder: your PLG or CS signal evidence

Brief-builder: customer language patterns

Brief-builder: the three intersections

Brief-builder: the Right-to-Win statement